Medtronic PLC (NYSE:MDT) – Research analysts at Oppenheimer Holdings dropped their Q4 2018 earnings per share (EPS) estimates for shares of Medtronic PLC in a research note issued to investors on Wednesday. Oppenheimer Holdings analyst S. Lichtman now expects that the medical technology company will post earnings of $1.41 per share for the quarter, down from their prior forecast of $1.43. Oppenheimer Holdings has a “Buy” rating and a $94.00 price target on the stock.

Several other equities analysts also recently weighed in on MDT. Zacks Investment Research downgraded shares of Medtronic PLC from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Deutsche Bank AG set a $96.00 price objective on shares of Medtronic PLC and gave the stock a “buy” rating in a research report on Monday, July 31st. BidaskClub cut shares of Medtronic PLC from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Cowen and Company set a $95.00 price target on shares of Medtronic PLC and gave the company a “buy” rating in a research report on Tuesday, August 22nd. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $90.00 price target on shares of Medtronic PLC in a research report on Monday, August 21st. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $88.02.

ILLEGAL ACTIVITY WARNING: “Q4 2018 EPS Estimates for Medtronic PLC Cut by Oppenheimer Holdings (MDT)” was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/11/23/q4-2018-eps-estimates-for-medtronic-plc-cut-by-oppenheimer-holdings-mdt.html.

Medtronic PLC (MDT) traded down $0.32 during trading hours on Thursday, hitting $82.34. 5,303,200 shares of the stock were exchanged, compared to its average volume of 4,935,842. Medtronic PLC has a 1 year low of $69.35 and a 1 year high of $89.72. The firm has a market capitalization of $111,970.49, a price-to-earnings ratio of 17.82, a P/E/G ratio of 2.18 and a beta of 1.00. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.40 and a quick ratio of 1.40.

Medtronic PLC (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.08. The firm had revenue of $7.05 billion during the quarter, compared to analysts’ expectations of $7.05 billion. Medtronic PLC had a net margin of 16.93% and a return on equity of 12.63%. The company’s revenue was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.12 EPS.

In other news, CEO Omar Ishrak sold 140,407 shares of the stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $81.63, for a total transaction of $11,461,423.41. Following the transaction, the chief executive officer now directly owns 668,503 shares in the company, valued at approximately $54,569,899.89. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Bryan C. Hanson sold 16,000 shares of the stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $78.03, for a total transaction of $1,248,480.00. The disclosure for this sale can be found here. Insiders sold a total of 172,407 shares of company stock worth $13,974,223 over the last quarter. Insiders own 0.31% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of MDT. Parkside Financial Bank & Trust boosted its stake in shares of Medtronic PLC by 22.4% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,146 shares of the medical technology company’s stock valued at $102,000 after buying an additional 210 shares during the last quarter. BDO Wealth Advisors LLC purchased a new position in shares of Medtronic PLC during the 2nd quarter valued at approximately $103,000. Motco boosted its stake in shares of Medtronic PLC by 8.7% during the 2nd quarter. Motco now owns 1,239 shares of the medical technology company’s stock valued at $110,000 after buying an additional 99 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in Medtronic PLC by 21.5% during the second quarter. Quadrant Capital Group LLC now owns 1,639 shares of the medical technology company’s stock worth $114,000 after purchasing an additional 290 shares during the last quarter. Finally, Israel Discount Bank of New York bought a new position in Medtronic PLC during the first quarter worth $117,000. 81.14% of the stock is owned by hedge funds and other institutional investors.

About Medtronic PLC

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Earnings History and Estimates for Medtronic PLC (NYSE:MDT)

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.